drugset / Trial / NCT06704269
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.
Timeline
- Start
- 2025-04-22
- Primary completion
- 2029-10-26
- Completion
- 2029-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rapcabtagene autoleucel | Cell therapy | — | Intravenous |